Brenda Thompson: Daily

Electronic parking brakes (EPB) are evolving beyond convenience features, becoming critical components for advanced driver-assistance systems (ADAS) and the push towards fully autonomous vehicles. A deep dive into the tech, market trends, & future outlook.

New AI tech embedded in standard CT scans promises earlier osteoporosis detection, potentially saving billions in healthcare costs and preventing debilitating fractures. But is it ready for prime time?

A surge in connected insulin storage devices, paired with growing demand for eco-friendly healthcare, is reshaping diabetes management. From AI-powered temperature monitoring to sustainable materials, innovation is cooling down challenges for patients.

From earthquake response to aging infrastructure, Geographic Information Systems (GIS) are at the heart of Japan's ambitious smart city initiatives, driving innovation and building a more resilient future.

New research highlights the expanding role of capnography beyond operating rooms, driven by rising respiratory illnesses, advanced tech, and a focus on patient safety. Market poised for continued growth.

New research reveals combining genetic risk scores with standard assessments significantly improves heart disease prediction, potentially preventing thousands of events annually.

Pharvaris is making waves in the Hereditary Angioedema (HAE) treatment landscape with its oral therapy, deucrictibant, showing strong efficacy and a favorable safety profile in late-stage trials. Could this be the breakthrough patients have been waiting for?

Sanofi and Regeneron’s Dupixent shows promising results in treating Allergic Fungal Rhinosinusitis, a debilitating condition affecting millions, potentially revolutionizing care and expanding the drug’s reach.

Positive Phase 2 trial data for Scancell’s iSCIB1+ combination therapy offers hope for advanced melanoma patients and positions the biotech for potential disruption in the immunotherapy market.

A new cross-modal imaging system is offering a non-invasive alternative to traditional skin biopsies, potentially reshaping dermatology practice and opening doors for personalized aesthetic treatments.

Inspira Technologies’ pending UAE approval signals a strategic move into the Gulf’s burgeoning critical care sector. How will this expansion reshape the region’s advanced medical landscape & what does it signal for the future of MedTech?

Breakthroughs in AI and wearable sensors are transforming CAR T-cell therapy, offering real-time monitoring and proactive intervention to mitigate the risk of potentially fatal neurotoxicity. Investors are taking notice.

A new oral treatment for hereditary angioedema (HAE) could dramatically improve the lives of children and teens with the rare, painful condition, while bolstering the position of biotech firm BioCryst.

Vivos Inc. is making strides in precision radiotherapy with a novel approach to cancer treatment, a strategic move into the Indian market, and growing traction in veterinary oncology – but faces regulatory and market challenges.

Transgene's innovative computational tool, VacDesignR®, aims to streamline the manufacturing of individualized cancer vaccines, potentially accelerating the field of personalized immunotherapy.

Swiss biotech BioVersys launches a key Phase 1 trial in China, aiming to combat the growing threat of carbapenem-resistant pneumonia with its innovative antibiotic, BV100.

PIH Health expands its robotic surgery program with a second da Vinci 5 system, enhancing precision, minimizing recovery times, and signaling a commitment to advanced patient care in a competitive market.

A breakthrough in precision medicine? Tevogen expands its investigational T-cell therapy to cover 65% of the US population, offering hope for a more inclusive approach to treating Long COVID and acute infections.

The Bay Area is set to host both the Super Bowl and World Cup in 2026. FleishmanHillard’s appointment as communications lead signals a complex undertaking. Will the region reap economic rewards or face growing pains?

HanchorBio’s HCB301, a novel immunotherapy tackling tumor resistance, is turning heads in the immuno-oncology space. Can this platform revitalize the fight against ‘cold’ tumors and reshape cancer treatment?